TBC1D22A Antibody

Introduction to TBC1D22A Antibody

TBC1D22A antibodies are immunological reagents designed to detect and analyze TBC1D22A (TBC1 domain family member 22A), a 517-amino-acid protein encoded by the TBC1D22A gene on human chromosome 22 . These antibodies facilitate research into the protein’s roles in Rab GTPase regulation, Golgi membrane dynamics, and disease mechanisms .

Key Features:

• Protein Structure: Contains a Rab-GAP TBC domain critical for GTPase-activating activity .

• Isoforms: Generated through alternative splicing .

• Gene Location: Chromosome 22q13.2 (Entrez Gene ID: 25771) .

• Ortholog Conservation: 92% sequence identity with mouse, 59% with rat .

Role in Golgi Dynamics and Viral Replication

• ACBD3 Interaction: TBC1D22A/B binds ACBD3 (acyl-CoA binding domain protein 3) at residues 246–321, competing with PI4KB (phosphatidylinositol 4-kinase beta) for binding . This competition modulates Golgi phosphatidylinositol 4-phosphate (PI4P) levels, influencing membrane organization .

• Viral Pathogenesis: Enteroviruses (e.g., poliovirus) exploit ACBD3-TBC1D22A interactions to hijack Golgi membranes for replication. Poliovirus 3A protein enhances TBC1D22A-ACBD3 binding, while Aichi virus 3A does not .

Clinical and Pathological Relevance

• Cancer: High TBC1D22A expression correlates with poor prognosis in ovarian serous cystadenocarcinoma .

• Neurological Disorders: Chromosome 22 mutations involving TBC1D22A are linked to autism, schizophrenia, and Phelan-McDermid syndrome .

• Leukemia: Chromosomal translocations involving 22q13.2 may contribute to BCR-Abl fusion proteins in Philadelphia chromosome-positive leukemias .

Technical Considerations

• Antibody Validation: Proteintech’s 18332-1-AP antibody detects endogenous TBC1D22A in HeLa cells at 59 kDa .

• Experimental Protocols: Optimal results require antigen retrieval with TE buffer (pH 9.0) for IHC and 1:500 dilution for WB .